Search

Your search keyword '"Lohaus F"' showing total 33 results
Start Over Author "Lohaus F" Publisher elsevier b.v.
33 results on '"Lohaus F"'

1. Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy

Author

Klement, R.J., Hoerner-Rieber, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M.J., Eich, H.C., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, K.H., Klass, N.D., Krempien, R., Lohaus, F., Petersen, C., Schrade, E., Wendt, T.G., Wittig, A., and Guckenberger, M.

Published
2018
Full Text
View/download PDF

2. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease

Author

Tanadini-Lang, S., Rieber, J., Filippi, A.R., Fode, M.M., Streblow, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M.J., Ernst, I., Flentje, M., Gerum, S., Hass, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, H., Klass, N.D., Krempien, R., Lohaus, F., Petersen, C., Schrade, E., Wendt, T.G., Wittig, A., Høyer, M., Ricardi, U., Sterzing, F., and Guckenberger, M.

Published
2017
Full Text
View/download PDF

3. PD-0064 Metastases-directed SRT combined with systemic therapy: 2y results of the TOaSTT real-world database

Author

Kroeze, S., Schaule, J., Spaas, M., Kahl, K.H., Verhoeff, J.J., Schneiders, F.L., Blanck, O., Lohaus, F., Rogers, S., Kaul, D., Benavente, S., Combs, S.E., Skazikis, G., Baumann, K., Popp, I., Koppe, F., Geinitz, H., de Jaeger, K.E., Siva, S., Stera, S., Wittig-Sauerwein, A., Lewitzki, V., Eckert, F., Schymalla, M.M., and Guckenberger, M.

Published
2023
Full Text
View/download PDF

15. PV-0044: Repeat sbrt for pulmonary oligo-metastases

Author

Guckenberger, M., Klement, R., Rieber, J., Adebahr, S., Andratschke, N., Blanck, O., Boda-Heggemann, J., Duma, M., Eble, M.J., Eich, H.T., Flentje, M., Gerum, S., Haas, P., Henkenberens, C., Hildebrandt, G., Imhoff, D., Kahl, H., Klass, N.D., Krempien, R., Lohaus, F., Petersen, C., Schrade, E., Wendt, T.G., and Wittig, A.

Published
2018
Full Text
View/download PDF

21. OC-0451: Tumour volume, hypoxia and cancer stem cells as prognosticators for LRC after primary RCT in HNSCC.

Author

Linge, A., Lohaus, F., Löck, S., Gudziol, V., Nowak, A., Von Neubeck, C., Tinhofer, I., Budach, V., Sak, A., Stuschke, M., Balermpas, P., Rödel, C., Avlar, M., Grosu, A.L., Abdollahi, A., Debus, J., Belka, C., Pigorsch, S., Combs, S.E., and Mönnich, D.

Subjects
*HEAD & neck cancer, *HEAD & neck cancer treatment, *RANDOMIZED controlled trials, *CANCER stem cells, *HYPOXEMIA, *PROGNOSIS
Published
2016
Full Text
View/download PDF

22. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.

Author

Eder, T., Hess, A.K., Konschak, R., Stromberger, C., Jöhrens, K., Fleischer, V., Hummel, M., Balermpas, P., von der Grün, J., Linge, A., Lohaus, F., Krause, M., Baumann, M., Stuschke, M., Zips, D., Grosu, A.L., Abdollahi, A., Debus, J., Belka, C., and Pigorsch, S.

Subjects
*CANCER patients, *CONFIDENCE intervals, *FORMALDEHYDE, *HEAD tumors, *HISTOLOGICAL techniques, *MEDICAL cooperation, *MULTIVARIATE analysis, *GENETIC mutation, *NECK tumors, *ONCOGENES, *ONCOLOGY, *PAPILLOMAVIRUSES, *RADIOTHERAPY, *RESEARCH, *RNA, *T cells, *TUMOR classification, *TREATMENT effectiveness, *DISEASE prevalence, *RETROSPECTIVE studies, *GENE expression profiling, *KAPLAN-Meier estimator, *SEQUENCE analysis, *ODDS ratio, *GENOTYPES, *CHEMORADIOTHERAPY, *TUMOR treatment
Abstract

Tumour mutational burden (TMB) estimated from whole exome sequencing or comprehensive gene panels has previously been established as predictive factor of response to immune checkpoint inhibitors (ICIs). Its predictive value for the efficacy of concurrent chemoradiation (cCRTX), a potential combination partner of ICI, remains unknown. The accuracy of TMB estimation by an in-house 327-gene panel was established in the Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma (HNSCC) data set. Interference of TMB with outcome after cCRTX was determined in a multicentre cohort of patients with locally advanced HNSCC uniformly treated with cCRTX. Targeted next-generation sequencing was successfully applied in 101 formalin-fixed, paraffin-embedded pretreatment tumour samples. In a subset of cases (n = 40), tumour RNA was used for immune-related gene expression profiling by the nanoString platform. TMB was correlated with TP53 genotype, human papilloma virus (HPV) status, immune expression signatures and survival parameters. Results were validated in the TCGA HNSCC cohort. A high accuracy of TMB estimation by the 327-gene panel was established. High TMB was significantly associated with an increased prevalence of TP53 mutations and immune gene expression patterns unrelated to T cell–inflamed gene expression profiles. Kaplan-Meier analysis revealed significantly reduced overall survival in the patient group with high TMB (hazard ratio for death: 1.79, 95% confidence interval: 1.02–3.14; P = 0.042) which remained significant after correcting for confounding factors in the multivariate model. The prognostic value of TMB was confirmed in the TCGA HNSCC cohort. High TMB identifies HNSCC patients with poor outcome after cCRTX who might preferentially benefit from CRTX-ICI combinations. • Accurate estimation of tumour mutational burden (TMB) by gene panel sequencing. • High TMB identifies patients with poor overall survival after chemoradiation. • TP53 mutations and unfavourable immune expression patterns associated with high TMB. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

26. OC-0582: Gene signatures predict loco-regional control after postoperative radiochemotherapy in HNSCC.

Author

Schmidt, S., Linge, A., Lohaus, F., Gudziol, V., Nowak, A., Tinhofer, I., Budach, V., Sak, A., Stuschke, M., Balermpas, P., Rödel, C., Avlar, M., Grosu, A.L., Abdollahi, A., Debus, J., Belka, C., Pigorsch, S., Combs, S.E., Mönnich, D., and Zips, D.

Subjects
*HEAD & neck cancer treatment, *CANCER chemotherapy, *CANCER radiotherapy, *POSTOPERATIVE care, *RADIOBIOLOGY
Published
2016
Full Text
View/download PDF

27. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.

Author

Tinhofer, I., Budach, V., Saki, M., Konschak, R., Niehr, F., Jöhrens, K., Weichert, W., Linge, A., Lohaus, F., Krause, M., Neumann, K., Endris, V., Sak, A., Stuschke, M., Balermpas, P., Rödel, C., Avlar, M., Grosu, A.L., Abdollahi, A., and Debus, J.

Subjects
*CISPLATIN, *SQUAMOUS cell carcinoma, *CANCER treatment, *HEAD tumors, *NECK tumors, *TUMOR suppressor genes, *ADJUVANT treatment of cancer, *CONFIDENCE intervals, *GENETIC mutation, *PAPILLOMAVIRUS diseases, *TREATMENT effectiveness, *INDIVIDUALIZED medicine, *DESCRIPTIVE statistics, *SEQUENCE analysis, *CHEMORADIOTHERAPY, *TUMOR treatment
Abstract

Background Despite clear differences in clinical presentation and outcome, squamous cell carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) infection or heavy tobacco/alcohol consumption are treated equally. Next-generation sequencing is expected to reveal novel targets for more individualised treatment. Patients and methods Tumour specimens from 208 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity, all uniformly treated with adjuvant cisplatin-based chemoradiation, were included. A customised panel covering 211 exons from 45 genes frequently altered in SCCHN was used for detection of non-synonymous point and frameshift mutations. Mutations were correlated with HPV status and treatment outcome. Results Mutational profiles and HPV status were successfully established for 179 cases. HPV– tumours showed an increased frequency of alterations in tumour suppressor genes compared to HPV+ cases ( TP53 67% versus 4%, CDKN2A 18% versus 0%). Conversely, HPV+ carcinomas were enriched for activating mutations in driver genes compared to HPV– cases ( PIK3CA 30% versus 12%, KRAS 6% versus 1%, and NRAS 4% versus 0%). Hotspot TP53 missense mutations in HPV– carcinomas correlated with an increased risk of locoregional recurrence (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.5–12.1, P = 0.006) and death (HR 2.2, 95% CI 1.1–4.4, P = 0.021). In HPV+ SCCHN, driver gene mutations were associated per trend with a higher risk of death (HR 3.9, 95% CI 0.7–21.1, P = 0.11). Conclusions Distinct mutation profiles in HPV– and HPV+ SCCHN identify subgroups with poor outcome after adjuvant chemoradiation. Mutant p53 and the phosphoinositide 3-kinase pathway were identified as potential druggable targets for subgroup-specific treatment optimisation. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

29. PO-1540: Radiomic models for validation in patients with locally advanced HNSCC treated with primary RTCx.

Author

Rabasco, A., Zwanenburg, A., Leger, S., Pilz, K., Lohaus, F., Linge, A., Zöphel, K., Kotzerke, J., Schreiber, A., Tinhofer, I., Budauch, V., Stuschke, M., Balermpas, P., Rödel, C., Ganswindt, U., Belka, C., Pigorsch, S., Combs, S.E., Mönnich, D., and Zips, D.

Subjects
*MODEL validation, *RADIOMICS
Abstract

Poster: Physics track: Radiobiological and predictive modelling, and radiomics PO-1540: Radiomic models for validation in patients with locally advanced HNSCC treated with primary RTCx A. Rabasco, A. Zwanenburg, S. Leger, K. Pilz, F. Lohaus, A. Linge, K. Zöphel, J. Kotzerke, A. Schreiber, I. Tinhofer, V. Budauch, M. Stuschke, P. Balermpas, C. Rödel, U. Ganswindt, C. Belka, S. Pigorsch, S.E. Combs, D. Mönnich, D. Zips, C. Richter, E.G.C. Troost, M. Krause, M. Baumann, S. Löck. [Extracted from the article]

Published
2020
Full Text
View/download PDF

30. OC-0570: Validating gene signatures in locally advanced HNSCC patients treated by PORT-C and in xenografts.

Author

Patil, S., Linge, A., Tawk, B., Gurtner, K., Großer, M., Lohaus, F., Gudziol, V., Nowak, A., Tinhofer, I., Budach, V., Stuschke, M., Balermpas, P., Rödel, C., Schäfer, H., Grosu, A., Abdollahi, A., Debus, J., Belka, C., Combs, S.E., and Mönnich, D.

Subjects
*GENES, *XENOGRAFTS, *PATIENTS
Abstract

Proffered Papers: Proffered papers 29: Head and neck OC-0570: Validating gene signatures in locally advanced HNSCC patients treated by PORT-C and in xenografts S. Patil, A. Linge, B. Tawk, K. Gurtner, M. Groà er, F. Lohaus, V. Gudziol, A. Nowak, I. Tinhofer, V. Budach, M. Stuschke, P. Balermpas, C. Rödel, H. Schäfer, A. Grosu, A. Abdollahi, J. Debus, C. Belka, S.E. Combs, D. Mönnich, D. Zips, G.B. Baretton, M. Krause, M. Baumann, S. Löck. [Extracted from the article]

Published
2020
Full Text
View/download PDF

33. SBRT for Lung Metastases: A Pooled Analysis of 651 Patients and 868 Lesions of the German Working Group Stereotactic Radiotherapy.

Author

Sterzing, F., Streblow, J., Scherer, K., Adebahr, S., Adratschke, N., Boda-Heggemann, J., Blanck, O., Duma, M., Ernst, I., Gademann, G., Ganswindt, U., Henkenberens, C., Imhoff, D., Kahl, H., Lohaus, F., Lubinski-de Lange, G., Maertin, A., Petersen, C., Wittig, A., and Guckenberger, M.

Subjects
*LUNG cancer treatment, *METASTASIS, *STEREOTACTIC radiotherapy, *PATIENT selection, *MEDICAL quality control
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results